TOP > 外国特許検索 > SUGAR CHAIN MARKER AS MEASURE OF DISEASE CONDITIONS OF HEPATIC DISEASES

SUGAR CHAIN MARKER AS MEASURE OF DISEASE CONDITIONS OF HEPATIC DISEASES

Foreign code F120006184
File No. S2009-0883
Posted date 2012年2月6日
Country 世界知的所有権機関(WIPO)
International application number 2010JP061791
International publication number WO 2011007764
Date of international filing 平成22年7月12日(2010.7.12)
Date of international publication 平成23年1月20日(2011.1.20)
Priority data
  • 特願2009-165795 (2009.7.14) JP
Title SUGAR CHAIN MARKER AS MEASURE OF DISEASE CONDITIONS OF HEPATIC DISEASES
Abstract Disclosed is a sugar chain marker which can detect hepatic diseases. More specifically disclosed is a sugar chain marker which can be used as a measure of the disease conditions of hepatic diseases. Further specifically disclosed is a sugar chain marker which can distinguish disease conditions depending on the stages of progression of hepatocellular carcinoma. A glycopeptide and a group of glycopeptides of which the sugar chain structure is changed specifically in hepatic diseases including hepatocellular carcinoma are identified among from serum glycoproteins. The glycopeptide and the group of glycopeptides can be used as a novel (glycopeptides and glycoprotein) sugar chain marker specific to the disease conditions of hepatic diseases.
Outline of related art and contending technology BACKGROUND ART
Is liver cancer, primary liver cancer and occurs in the liver, can be largely divided into a metastatic liver cancer, primary liver cancer is hepatocellular carcinoma in 90% is called.
Hepatocellular cancer patients, as the underlying disease, hepatitis C virus, hepatitis B virus infection or in many cases, from acute viral hepatitis, chronic viral hepatitis, liver cirrhosis and then proceeds to the, after suffering from viral hepatitis, after a prolonged period of time, often to cancer for the first time. In cirrhosis, inflammation by repeating reproduction, when normal hepatocytes is reduced, to the organ is composed of fibrous tissue changes. For example, hepatitis C patients, only 300 million Climate, Chinese Africa is, are said to be 1000 or greater. In addition, type B, hepatitis C in case of a patient, rate from chronic hepatitis in rats, 0.8% per year (F1) in the mild chronic hepatitis, chronic hepatitis (F2) moderate but per year in 0.9%, (F3) becomes severe chronic hepatitis and 3.5% per year, further increasing the likelihood of cancer from liver cirrhosis (F4), also increases to 7% per year (Fig. 2, 3). Also liver disease can be, along with the progression of the pathological condition, first begins to disappear function in chronic hepatitis, liver cirrhosis appears in the pathological structure, such as liver fibrosis proceeds, histology changes (Fig. 1).
In the treatment of cancer, early detection of cancer is important, in the case of hepatocellular carcinoma at an early stage discovery of cancer treatment, a great effect on the postoperative prognosis. 5 - Year survival rate is hepatectomy treatment, at 80% if the stage I, stage IV is only 38%.
Liver cancer markers include, up to now, α - fetoprotein (AFP) and protein induced by Vitamin K absence or antagonist-II(PIVKA-II) is known (patent document 1, 2) is, its specificity, sensitivity is not fully. For this reason, currently, screening for the early detection of liver cancer, liver cancer marker, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI) an image such as the inspection is taking place.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
  • NAGOYA CITY UNIVERSITY
  • NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE
  • Inventor
  • NARIMATSU Hisashi
  • HIRABAYASHI Jun
  • IKEHARA Yuzuru
  • ANGATA Takashi
  • KAJI Hiroyuki
  • KUNO Atsushi
  • OOKURA Takashi
  • SHIKANAI Toshihide
  • SOGABE Maki
  • TOGAYACHI Akira
  • OCHOU Makoto
  • TANAKA Yasuhito
  • MIZOKAMI Masashi
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close